Core Viewpoint - The company is planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and a 40% stake in Zhejiang Beid Pharmaceutical Co., Ltd. through a share issuance and/or cash payment, while also raising supporting funds for this transaction [1] Group 1: Transaction Details - The transaction is currently in the planning stage, and the valuations for Xipu Materials and Beid Pharmaceutical have not yet been finalized [1] - This transaction is expected to constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1] - The transaction will not result in a change of the company's actual controller and does not constitute a restructuring listing [1] Group 2: Stock Suspension - According to regulations from the Shenzhen Stock Exchange, the company's stock will be suspended from trading starting September 8, 2025 [1]
向日葵(300111.SZ)拟收购兮璞材料控股权及贝得药业40%股权 9月8日起停牌